The research review titled, “Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy,” published in the March 2020 Journal of Circulation Research, provides the basis for the involvement of mitochondrial toxicity in the different functional hallmarks of anthracycline toxicity. The goal of this study is to understand the molecular determinants of a progressive deterioration of the functional integrity of mitochondria that establishes a historic record of past drug treatments (mitochondrial memory) and renders the cancer patient susceptible to subsequent regimens of drug therapy.

Understanding the key role of mitochondria in doxorubicin-induced cardiomyopathy is essential to reduce the barriers that so dramatically limit the clinical success of this essential anticancer chemotherapy.

"Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy"
K.B. Wallace, V.I. Sardao and P.J. Olveira
March 27, 2020 | Vol 126, Issue 7
Read the full article here.